

At page 38, lines 20-23, please replace the existing table with the following table:

D²

	<u>Control (vector alone)</u>	<u>flt3-L</u>	<u>IL-3</u>	<u>flt3-L + IL-3</u>
[³ H]-thymidine incorporation (CPM)	100	1800	3000	9100

At page 43, lines 1-13, please replace the existing table with the following table:

TABLE IV

Effect of flt3-L Overexpression in Transgenic Mice

D³

<u>Marker</u>	<u>Percentage of Positive Cells</u>			
	<u>Unrelated Control</u>	<u>Littermate Control</u>	<u>Transgenic #1</u>	<u>Transgenic #2</u>
B220	30.64	27.17	45.84	48.78
sIgM	3.54	2.41	1.94	1.14
S7(CD43)	54.43	45.44	46.11	50.59
SCA-1	10.92	11.74	19.45	27.37
CD4	6.94	8.72	12.21	14.05
Mac-1	36.80	27.15	21.39	18.63

In the claims:

Please replace claim 2 with the following twice amended claim:

E1
4
1) 2. (twice amended) A method for ~~expanding~~ hematopoietic cells comprising contacting the cells with flt3-L, wherein the flt3-L is in an amount sufficient to cause expansion of the hematopoietic cells.

Remarks

The specification has been amended to claim the appropriate effective priority date, namely, December 7, 1993, for the current claims. In addition, the specification has been amended to address the Examiner's objection to Table II on page 38, and to correct several similar informalities that were noticed in Tables I and IV. Marked-up copies of pages 38 and 42 are enclosed. Claim 2 has been amended to clarify the language. No new matter has been added.